Having a large clinical trial portfolio means giving patients treatment options often not available anywhere else, and years before they become the standard of care. To learn more about Karmanos Cancer Institute clinical trials or to see if a trial is right for you, please call 1-800-KARMANOS (1-800-527-6266) or request an appointment below
  • First-in-human, Phase I/II, Multicenter, Open-Label Study of EMB-01 in Patients with Advanced/Metastatic Solid Tumors

    Cancer Categories
    • Gastrointestinal (GI),Lung
    Karmanos Trial ID
    • 2018-158
    NCT ID
    • NCT03797391
    Age Group
    • Adult
    Scope
    • National
    PhaseClick for Clinical Trial Phase DefinitionPhase I
    Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
    • Phase I/II
    Principal Investigator

    Objective:

    Phase I
    Primary Objectives:
    • To evaluate the safety and tolerability of EMB-01 when administered intravenously (IV)
    • To determine Maximum Tolerated Dose (MTD) and/or the RP2D of EMB-01
    Secondary Objectives:
    • To characterize PK of EMB-01
    • To estimate preliminary antitumor activity of EMB-01
    • To evaluate the incidence of immunogenicity of EMB-01
    Phase II
    Primary Objectives:
    • To estimate preliminary antitumor activity of EMB-01 at RP2D
    • To continue evaluate the safety and tolerability of EMB-01
    Secondary Objectives:
    • To continue characterize PK and immunogenicity of EMB-01
  • Locations

    Locations

    Karmanos Cancer Institute - Detroit Headquarters

    4100 John R
    Detroit, MI 48201
    Get Directions
    Phone: 800-527-6266

    Karmanos Cancer Institute at Lawrence and Idell Weisberg Cancer Treatment Center - Farmington Hills

    31995 Northwestern Hwy
    Farmington Hills, MI 48334
    Get Directions
    Phone: 800-527-6266